229 related articles for article (PubMed ID: 19152412)
1. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
[TBL] [Abstract][Full Text] [Related]
3. [Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
Jin YJ; Park YK; Yun GJ; Lee HC; Jeong SH; Kim GM; Lim YS; Chung YH; Lee YS; Suh DJ
Korean J Hepatol; 2010 Jun; 16(2):158-67. PubMed ID: 20606500
[TBL] [Abstract][Full Text] [Related]
4. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
5. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.
Hayashi K; Katano Y; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
J Gastroenterol Hepatol; 2015 Jan; 30(1):178-83. PubMed ID: 24995561
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
[TBL] [Abstract][Full Text] [Related]
9. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
[TBL] [Abstract][Full Text] [Related]
10. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O
Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958
[TBL] [Abstract][Full Text] [Related]
11. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
[TBL] [Abstract][Full Text] [Related]
16. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
17. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
[TBL] [Abstract][Full Text] [Related]
18. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
19. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
[TBL] [Abstract][Full Text] [Related]
20. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
